House Lawmakers Introduce Bipartisan Bill to Allow Methadone Access Through Pharmacies

Congressmen Donald Norcross (D-N.J.), Mike Lawler (R-N.Y.), and Paul Tonko (D-N.Y.) introduced bipartisan legislation Monday that would fundamentally reshape how Americans access methadone for opioid addiction treatment. The Modernizing Opioid Treatment Access Act 2.0 (MOTAA 2.0) would allow board-certified addiction physicians and psychiatrists to prescribe methadone through local pharmacies—ending a 50-year monopoly by specialized opioid treatment programs that leaves the vast majority of U.S. counties without access.

The bill arrives one month after Senators Ed Markey and Rand Paul introduced a Senate companion version, creating parallel momentum in both chambers of Congress for the most significant restructuring of addiction medication access since the Nixon administration.

The Geography of Exclusion

Under current federal regulations, methadone for opioid use disorder can only be dispensed through approximately 2,000 federally regulated opioid treatment programs (OTPs). This restriction creates stark geographic inequities: approximately 80% of American counties lack any OTP facility, forcing patients in rural and underserved areas to travel extraordinary distances for daily medication.

The disparity is particularly acute when compared to standard healthcare access. While pharmacies that could dispense methadone exist in virtually every community, patients seeking the medication must navigate a parallel system that requires them to visit specialized clinics—often daily during initial treatment phases. The World Health Organization has recommended methadone as an essential medicine for opioid dependence since 2004, yet the United States maintains stricter access controls than nearly any other developed nation.

"The fact that only a fraction of people can access the most effective, readily-available treatment for opioid addiction is simply a policy choice," said Congressman Norcross, who has led previous iterations of this legislation. "And it's a bad choice that's needlessly costing lives."

The Private Equity Dimension

The House legislation highlights a factor rarely discussed in addiction policy debates: the growing role of private equity in the OTP industry. According to data cited by the bill's sponsors, nearly one-third of opioid treatment programs are now owned by private equity firms—a higher concentration than almost any other medical specialty.

This consolidation has produced mixed results. While private investment has expanded some treatment capacity, it has also financed organized opposition to regulatory reforms that would increase competition. The House sponsors explicitly frame their bill as a response to what they describe as "private-equity monopolies who profit from addiction services."

Research published in Health Affairs found that private equity ownership of OTPs has grown substantially without corresponding increases in patient access or measurable improvements in outcomes. The financial incentives of the current system—where patients must visit facilities daily and pay for bundled services—create structural resistance to reforms that would allow pharmacy-based dispensing.

Bipartisan Coalition in the House

The House version has attracted support from more than 50 healthcare and recovery organizations, ranging from the American Medical Association and American Society of Addiction Medicine to advocacy groups like Faces & Voices of Recovery and Shatterproof. This coalition spans the ideological spectrum, united by evidence showing methadone reduces all-cause mortality by over 50% among patients with opioid use disorder.

Congressman Lawler, representing a suburban New York district that has experienced significant opioid mortality, emphasized practical outcomes over ideology. "The opioid epidemic has devastated families across New York and our nation, showing the need to make proven, lifesaving treatment more accessible," he said. "This bipartisan legislation gives qualified addiction specialists the ability to prescribe methadone for opioid addiction through local pharmacies, helping patients access care closer to home safely."

Congressman Tonko, whose district includes Albany and surrounding communities, framed the issue through the lens of long-standing clinical evidence. "For decades, methadone has been a safe, proven, and effective treatment that saves lives and helps millions living with the disease of addiction," he said. "Congress must do all in its power to ensure our communities can access these evidence-based treatments."

New Provisions in Version 2.0

The House legislation builds upon earlier versions by incorporating additional safety guardrails and administrative flexibility. Most significantly, the bill grants the Department of Health and Human Services authority to designate future categories of licensed providers for methadone prescribing without requiring additional congressional legislation.

This provision addresses a practical limitation of the current healthcare workforce. While approximately 2,000 physicians hold board certification in addiction medicine, the ongoing opioid crisis has created demand that outstrips specialist capacity. The HHS authorization would allow the department to expand prescribing privileges to additional provider types—such as appropriately trained nurse practitioners or physician assistants—as workforce needs evolve.

The bill maintains strict eligibility requirements for initial authorization. Only physicians board-certified in addiction medicine or psychiatry would be permitted to prescribe methadone for opioid use disorder, ensuring that prescribing authority remains with clinicians who have specialized training in managing complex substance use disorders.

The Senate Parallel

The House introduction creates coordinated pressure across Capitol Hill. Senators Ed Markey (D-Mass.) and Rand Paul (R-Ky.) introduced their version of MOTAA 2.0 in late June, with a bipartisan cosponsor list including Elizabeth Warren, Maggie Hassan, Cory Booker, and Bernie Sanders. The Senate bill contains similar provisions for pharmacy-based dispensing through board-certified addiction physicians.

The parallel tracks reflect growing recognition that the current OTP system, while effective for patients who can access it, creates insurmountable barriers for millions of Americans. Research consistently shows that methadone and buprenorphine—the two primary medications for opioid use disorder—reduce mortality by approximately 50% compared to no treatment. Yet methadone remains significantly underutilized relative to its clinical potential.

International Context

The United States stands virtually alone among developed nations in restricting methadone to specialized clinic settings. Canada, the United Kingdom, Australia, and most European countries allow qualified physicians to prescribe methadone through standard pharmacy channels. Patients in these systems typically receive take-home supplies after demonstrating treatment stability, reducing the logistical burdens that cause many Americans to abandon care.

Studies from these countries have not found the diversion crises that American policymakers feared when establishing the OTP system in the early 1970s. Instead, pharmacy-based dispensing appears to improve treatment retention by eliminating barriers related to transportation, employment, and childcare. The flexibility of community-based dispensing aligns with modern understandings of addiction as a chronic medical condition best managed through integrated primary care.

The Scale of Unmet Need

Behind the legislative debate lie stark statistics. Despite three consecutive years of declining overdose deaths, more than 44,000 Americans died of opioid overdoses in 2025—approximately 120 preventable deaths every day. An estimated five million people in the United States have an opioid use disorder, yet fewer than 20% receive any form of medication-assisted treatment.

The gap between need and access is particularly pronounced for methadone. While buprenorphine prescribing has expanded significantly following the elimination of the X-waiver requirement, methadone remains confined to a limited network of specialized facilities. Patients in rural Montana, western Kansas, or eastern Oregon may face drives of several hours to reach the nearest OTP—an insurmountable barrier for those without reliable transportation or flexible employment.

Uncertain Prospects

The bill faces significant hurdles before becoming law. While opioid legislation has historically attracted bipartisan support, the specific question of methadone deregulation remains contentious. Some OTP operators argue that pharmacy dispensing would fragment care and reduce access to the counseling and support services that clinics currently bundle with medication.

The Trump administration's posture adds uncertainty. HHS Secretary Robert F. Kennedy Jr. has expressed support for expanding medication-assisted treatment broadly, but some administration officials have simultaneously signaled skepticism about long-term maintenance models. The administration's broader restructuring of SAMHSA and shifts in federal grant priorities could affect the bill's political environment.

Nevertheless, the coordinated introduction in both chambers—with bipartisan sponsorship in each—represents the most serious legislative push for methadone reform in decades. For the millions of Americans living in counties without OTP access, the outcome could determine whether life-saving treatment remains within reach.